Vita Life Sciences Ltd
Vita Life Sciences Ltd is a pharmaceutical company focused on the development and commercialization of nutraceutical and pharmaceutical products, primarily in the areas of women's health and wellness.
Business. Vita Life Sciences Ltd (VLS.AX) is a pharmaceutical company listed on the Australian Securities Exchange. The firm operates within the Healthcare sector, specifically focusing on pharmaceuticals and medical research. It generates revenue through the sale of products. The company is headquartered in Australia.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Vita Life Sciences Ltd (VLS.AX) is a pharmaceutical company listed on the Australian Securities Exchange. The firm operates within the Healthcare sector, specifically focusing on pharmaceuticals and medical research. It generates revenue through the sale of products. The company is headquartered in Australia.
Vita Life Sciences operates with a fully diluted share count of 54,394,547 shares, with no additional shares outstanding in the diluted count, indicating no dilution from stock options or convertible instruments. However, the company's liquidity position could not be assessed due to the absence of balance-sheet inputs and no going-concern language in the source documents.
The company's profitability and return metrics are not available in the current valuation snapshot, and no industry-specific preferred metrics are provided for comparison. This lack of data limits the ability to assess its performance relative to industry medians or to evaluate its operational efficiency.
Vita Life Sciences does not disclose segment or geographic revenue breakdowns in the available data, making it difficult to assess the concentration of its revenue sources or geographic exposure. This lack of transparency could pose a risk to investors seeking to understand the company's diversification and resilience to regional economic shifts.
The company's growth trajectory is not quantified in the available data, and no numeric deltas are provided for the current or next fiscal year. Without clear revenue growth projections or historical performance, it is challenging to assess the company's momentum or future potential.
The risk assessment indicates a low level of dilution risk, but the liquidity risk remains unassessed due to the absence of balance-sheet data. The company's financial health and ability to meet short-term obligations are therefore unclear.
Recent events and filings are not detailed in the available data, which limits the ability to assess the company's strategic direction or operational developments. Investors should monitor future disclosures for insights into management's plans and any material changes in the company's operations.
- Vita Life Sciences operates in the pharmaceuticals industry with a focus on women's health and wellness.
- The company's liquidity position could not be assessed due to missing balance-sheet data.
- No segment or geographic revenue breakdown is available, limiting visibility into diversification.
- Growth projections and profitability metrics are not disclosed in the available data.
- Dilution risk is low, but liquidity risk remains unassessed.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Revenue A$79.5M, +8,3% YoY; Operating income −1,8% YoY.
- ▍Revenue A$79.5M, +8,3% YoY
- ▍Operating income −1,8% YoY
- ▍Net income −3,3% YoY
- ▍Free cash flow −27,7% YoY
- ▍Net margin 11.0%
Revenue A$73.4M, +9,8% YoY; Operating income +13,0% YoY.
- ▍Revenue A$73.4M, +9,8% YoY
- ▍Operating income +13,0% YoY
- ▍Net income +28,2% YoY
- ▍Free cash flow +16,8% YoY
- ▍Net margin 12.4%
Revenue A$66.9M, +17,1% YoY; Operating income −4,7% YoY.
- ▍Revenue A$66.9M, +17,1% YoY
- ▍Operating income −4,7% YoY
- ▍Net income −14,6% YoY
- ▍Free cash flow −15,0% YoY
- ▍Net margin 10.6%
Valuation FY
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Vita Life Sciences Ltd Market data — financials · 2026-05-29